RYTM - RHYTHM PHARMACEUTICALS, INC.

91.46
0.460   0.503%

Share volume: 661,337
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$91.00
0.46
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.67%
1 Month
-11.73%
3 Months
-13.04%
6 Months
-8.33%
1 Year
77.11%
2 Year
122.53%
Key data
Stock price
$91.46
P/E Ratio 
0.00
DAY RANGE
$89.12 - $91.70
EPS 
-$3.11
52 WEEK RANGE
$45.90 - $122.20
52 WEEK CHANGE
$80.07
MARKET CAP 
7.143 B
YIELD 
N/A
SHARES OUTSTANDING 
68.285 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.78
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$977,144
AVERAGE 30 VOLUME 
$833,586
Company detail
CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.

Recent news